Le Lézard
Classified in: Health
Subject: FDA

EOI Announces FDA Clearance for the FLXfit15, the Only 3D Articulated Expandable Cage With 15 degrees of Lordosis Correction


OR AKIVA, Israel, September 28, 2017 /PRNewswire/ --

Expanding Orthopedics Inc. (EOI), a privately-held medical device company focused on developing and commercializing innovative expandable devices for spine surgery, today announced FDA 510(k) clearance for the FLXfittm15, enhancing the already successful FLXfittm 3D Expandable Cage System. The FLXfittm15 will expand the surgeon's flexibility and capability by offering a family of products in different length options with infinitely adjustable expansion and lordosis correction of upto 4mm and 15?.

Dale Binke, EOI's VP of US Sales, notes that, "One of the major trends in fusion surgeries is progression towards MIS style procedures, inpatient or outpatient." However, Dale explains, "There is an inherent challenge in inserting a large interbody cage that restores lumbar lordosis while controlling sagittal and coronal alignment." He adds, "The FLXfit expandable cage is already providing the ultimate expandable TLIF solution, combining the best-in-class footprint that can be delivered through a MIS window and a unique expansion mechanism that restores lordosis." Dale summarizes, "With the FLXfit15tm, EOI's engineering team has pushed the envelope a step further by combining an articulating cage with optimal footprint which can be easily delivered and expanded in a controlled manner up to 4mm and 15? of lordotic restoration."

Expandable cages are gaining market momentum and play a key role in successful fusion procedures. Ofer Bokobza, CEO of Expanding Orthopedics, comments, "The FLXfittm System has already trail blazed the way for anatomical fit, expandable cages by providing great clinical promise so far." Ofer says, "The FLXfit15tm will further enhance the anatomical fit with its 15? lordosis and the shorter footprint version (32mm) will offer great flexibility in treating patients with smaller anatomies." He concludes, "We are thrilled with the release of the FLXfittm15 in the US and certain that the enhanced versatility of the new FLXfittm family will help gain a greater share in the fusion surgery market, both in MIS and open approaches."

About Expanding Orthopedics Inc. 

Expanding Orthopedics Inc. is medical device company developing and marketing innovative products designed to address unmet clinical needs for spine care and improve long-term patients' outcome. The Company is spearheaded by a seasoned management team, and is advised by a prominent team of spine surgeons. EOI owns a broad patent portfolio around anatomically fit, expandable devices for enhanced stability through a minimally invasive approach.

Contact info:
David Elkaim,
VP Marketing and Sales
E-mail: [email protected]
Phone: (347)-3219683

SOURCE Expanding Orthopedics Inc.


These press releases may also interest you

at 16:35
Geron Corporation , a late-stage clinical biopharmaceutical company, today announced that it will release its first quarter 2024 financial results and business highlights before the market opens on Thursday, May 2, 2024 via press release, which will...

at 16:35
Tilray Brands, Inc. , a leader in the craft beer and cannabis-lifestyle industries, celebrates high honors and awards at the 2024 Craft Brewer's Conference and World Beer Cup. 10 Barrel Brewing won four craft beer awards and 10...

at 16:30
In an important step toward driving long-term affordability and access to treatments for chronic and complex conditions, Evernorth Health Services announced that it will have a Humira® biosimilar available for $0 out of pocket for eligible...

at 16:28
Dr. Siva Mohan, Co-Founder and Chief Medical Officer of RazorMetrics, an Austin-based drug cost reduction platform, is the Best Entrepreneur - Health Products & Services Status: Silver Stevie Winner from the American Business Awards. The Stevie®...

at 16:20
The Board of Directors of Revvity , today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 9, 2024 to all shareholders of record at the close of business on July 19, 2024. About Revvity ...

at 16:20
Edwards Lifesciences today reported financial results for the quarter ended March 31, 2024. Highlights and Outlook Q1 sales grew 10% on a reported and constant currency1 basis to $1.6 billion Q1 TAVR sales grew 6%; constant currency sales...



News published on and distributed by: